Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuro-Cells for (Sub)Acute Spinal Cord Injury
NCT03935724Phase 3Active, not recruiting
- Sponsor
- Neuroplast
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Neuro-Cells in spinal cord injury (SCI) (4 arms), sponsored by Neuroplast. Primary endpoints: Physical changes after intrathecal intervention with Neuro-Cells at 9 months and Increase of motor scores after intrathecal invervention with Neuro-Cells at 6 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
Neuro-Cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT03935724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935724.